10,000 participant randomized Phase 2b study will evaluate Gritstone’s self-amplifying mRNA (samRNA) vaccine candidate containing Spike plus other viral targets with an approved vaccine against COVID-19 --
-- Contract is part of ‘Project NextGen,’ an initiative by the U.S. Department of Health and Human Services to advance a pipeline of new, innovative vaccines and therapeutics providing broader and more durable protection for COVID-19 --
https://finance.yahoo.com/news/gritstone-bio-awarded-barda-contract-200100476.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.